Clinical Report: Lilly’s tirzepatide shows benefit in pre-diabetics

New data for tirzepatide in pre-diabetic patients drove another big gain for Eli Lilly on Tuesday, lifting its market cap by nearly $27 billion.

Eli Lilly and Co. (NYSE:LLY) announced results from a secondary endpoint of the Phase III SURMOUNT-1 study showing that among pre-diabetic patients who had obesity or were overweight, there was a 94% reduction in the risk of developing Type II diabetes at 176 weeks. The same group also had sustained weight loss, with the top dose showing a 22.9% average decrease in weight compared with 2.1% for placebo...